Aprea Therapeutics, Inc. (APRE): Nasdaq/NYSE listing notice — Aprea Therapeutics receives Nasdaq bid price deficiency notice; stock at risk of delisting

Aprea Therapeutics, Inc.

Closing bid below $1.00 for 30 consecutive business days triggered Nasdaq deficiency letter.
Company has 180 calendar days (until July 22, 2026) to regain compliance via $1.00 close for 10 consecutive days.
If not cured by July 22, Aprea may qualify for a second 180-day period if it meets other listing standards.
Company may consider a reverse stock split to cure the deficiency but no assurance of compliance.
Stock continues trading on Nasdaq Capital Market under symbol APRE with no immediate delisting effect.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Aprea Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

January 23, 2026, Aprea Therapeutics, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Aprea Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-006267

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.